Navigation Links
The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster
Date:7/20/2009

WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and FORMA Therapeutics today announced a partnership to accelerate LLS's pipeline of research projects entering late pre-clinical development.

The collaboration will begin with a selection of ten small molecule candidates, discovered by LLS grant-funded academic researchers, deemed to have the most promise of advancing into clinical trials in the shortest period of time. FORMA will use its proprietary Computational Solvent (CS) Mapping technology to aid in structure based drug design with expert computer modeling, screening and medicinal chemistry competence to optimize and prioritize molecules that LLS and its partners may take to the clinic.

The partnership between LLS and FORMA is the latest in LLS's Therapy Acceleration Program (TAP), a bold initiative intended to advance therapies with high prospects of providing near-term benefit to patients suffering from blood cancers. Through TAP, LLS is taking a results-oriented approach, partnering directly with biotechnology companies to move promising therapies more quickly along the FDA drug approval critical path.

"With its sophisticated technology suite and internal expertise to expeditiously progress the development of novel therapies, FORMA is an ideal partner to help LLS identify and optimize the most promising drug candidates and to achieve our mission of advancing life-saving blood cancer therapeutics," said John Walter LLS's chief executive officer.

"LLS has assembled a promising portfolio of innovative programs to combat a wide range of hematological cancers," says FORMA CEO Steve Tregay, Ph.D. "The team at FORMA is excited to be working with LLS on this bold initiative by providing our unique suite of drug discovery technologies to quickly translate science from the laboratory to patients in clinical trials."

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

About FORMA Therapeutics

FORMA Therapeutics is integrating transformative chemistry and biology to unlock the best targets and pathways that genomic medicine has revealed. Capitalizing on the targets and pathways validated by the Cancer Genome Atlas Project and other related efforts, FORMA is developing a new generation of cancer therapies aimed at previously elusive drug targets. The Company is achieving this by applying its proprietary cell-based screening, structure-guided drug discovery and Diversity Oriented Synthesis (DOS) technologies, which FORMA also uses to discover novel compounds for its partners in indications beyond oncology. FORMA is a global company headquartered in Cambridge, MA with additional research operations in Connecticut, Singapore and Beijing. www.formatherapeutics.com.

    Contact: LLS: Andrea Greif
            (914) 821-8958  andrea.greif@lls.org

    FORMA:   Steven Tregay, CEO
             (617) 679-1970

    FORMA Media Contact:
    MacDougall Biomedical Communications
    Douglas MacDougall or Jennifer Conrad
    (781) 235-3060


'/>"/>
SOURCE The Leukemia & Lymphoma Society (LLS)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Leukemia/Lymphoma Society Pleased to Announce Partnership in Southern Ohio with Eisen Marketing Group
2. 2009 recipient of minority scholar award begins clinical research on leukemia
3. Toronto researchers discovery points to a new treatment avenue for acute myeloid leukemia
4. New Drug Could Work Against Leukemia
5. Leukemia & Lymphoma Society Recognizes Aurora Physician as Man of the Year
6. For Kids With Leukemia, Radiation May Be Safe to Skip
7. The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense
8. Taking Aim at Relapse of Leukemia in Kids
9. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
10. Study IDs benefit of donor SCT for adults with acute myeloid leukemia
11. Donor Stem-Cell Transplant Best For Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
Breaking Medicine Technology: